Track record · closed signal

Abbott Laboratories (ABT) — closed signal from January 31, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 1, 2026.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$105.00 – $110.00Entry zone — fair-value band

$109.30Published — price the day we called it

$120.23Target — the price the thesis aimed for

$116.82Peak — highest point inside the window, not a realized return

$89.46Window close — end-of-window price, context only

What happened

Partial

Reached 69% of the predicted growth at its peak, without hitting the target.

Peak price

$116.82

peak on February 27, 2026 — not a realized return

Peak gain

+6.9%

peak, from the publication price

Window close

$89.46

end-of-window price, context only

Days to target

—

Window

January 31, 2026 – May 1, 2026

The thesis — published January 31, 2026

Predicted growth

+10%

over the measurement window

Target price

$120.23

the price the thesis aimed for

Entry zone

$105.00 – $110.00

the fair-value band we waited for

Price at publication

$109.30

published January 31, 2026

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott recently fell after missing sales expectations and facing problems in its nutrition business. Many analysts now think device and diabetes products could lead a recovery, which may attract buyers if the selling calms. This is a short-term trade idea to buy in stages near support with careful risk limits, not a guarantee of a quick return to prior highs.

Primary drivers

Medical devices and diabetes care can restart growth
Price could bounce back if selling pressure eases
Analysts are shifting to a recovery story
Buying in stages limits downside risk

How it played out

ABT: target was not reached

Lyra published ABT at $109.3 on 2026-01-31 with a short-term thesis for 10% expected growth. The thesis pointed to medical devices and diabetes care as possible growth drivers, easing selling pressure, a recovery story among analysts, and buying in stages near support with risk limits.

Inside the window from 2026-01-31 to 2026-05-01, ABT peaked at $116.82 on 2026-02-27, a 6.9% gain. It stayed below the $120.23 target. By the end of the window, it was at $89.46. The thesis partially played out early, then missed the target and ended weak.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals